Hugh S Taylor1, Aya Tal1, Lubna Pal1, Fangyong Li2, Dennis M Black3, Eliot A Brinton4, Matthew J Budoff5, Marcelle I Cedars6, Wei Du2, Howard N Hodis7, Rogerio A Lobo8, JoAnn E Manson9, George R Merriam10,11, Virginia M Miller12,13, Frederick Naftolin14, Genevieve Neal-Perry15, Nanette F Santoro16, Sherman M Harman17,18. 1. Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut. 2. Yale Center for Analytical Sciences, Yale University School of Public Health, New Haven, Connecticut. 3. Epidemiology and Biostatistics, University of California at San Francisco. 4. Utah Foundation for Biomedical Research, Salt Lake City. 5. Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California. 6. Obstetrics and Gynecology, University of California at San Francisco. 7. Atherosclerosis Research Unit, University of Southern California, Los Angeles. 8. Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York. 9. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 10. Veterans Affairs Puget Sound Health Care System, Tacoma, Washington. 11. Division of Metabolism, Endocrinology and Nutrition, University of Washington, Tacoma. 12. Department of Surgery, Mayo Clinic, Rochester, Minnesota. 13. Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota. 14. Obstetrics and Gynecology, New York University School of Medicine, New York. 15. Division of Reproductive Endocrinology and Infertility, University of Washington Medical School, Seattle. 16. Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora. 17. Kronos Longevity Research Institute, Phoenix, Arizona. 18. Division of Endocrinology, Phoenix Veterans Affairs Medical Center, Phoenix, Arizona.
Abstract
Importance: Sexual dysfunction, an important determinant of women's health and quality of life, is commonly associated with declining estrogen levels around the menopausal transition. Objective: To determine the effects of oral or transdermal estrogen therapy vs placebo on sexual function in postmenopausal women. Design, Setting, and Participants: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), a 4-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women. Of 727 KEEPS enrollees, 670 agreed to participate in this multicenter ancillary study. Women were 42 to 58 years old, within 36 months from last menstrual period. Data were collected from July 2005 through June 2008 and analyzed from July 2010 through June 2017. Interventions: Women were randomized to either 0.45 mg/d oral conjugated equine estrogens (o-CEE), 50 µg/d transdermal 17β-estradiol (t-E2), or placebo. Participants also received 200 mg oral micronized progesterone (if randomized to o-CEE or t-E2) or placebo (if randomized to placebo estrogens) for 12 days each month. Main Outcomes and Measures: Aspects of sexual function and experience (desire, arousal, lubrication, orgasm, satisfaction, and pain) were assessed using the Female Sexual Function Inventory (FSFI; range, 0-36 points; higher scores indicate better sexual function). Low sexual function (LSF) was defined as an FSFI overall score of less than 26.55. Distress related to low FSFI score (required for the diagnosis of sexual dysfunction) was not evaluated. Results: The 670 participants had a mean (SD) age of 52.7 (2.6) years. The t-E2 treatment was associated with a significant yet moderate improvement in the FSFI overall score across all time points compared with placebo (average efficacy, 2.6; 95% CI, 1.11-4.10; adjusted P = .002). With o-CEE treatment, there was no significant difference in FSFI overall score compared with placebo (mean efficacy, 1.4; 95% CI, -0.1 to 2.8; adjusted P = .13). There was no difference in FSFI overall score between the t-E2 and o-CEE groups on average across 48 months (adjusted P = .22). In the individual domains of sexual function, t-E2 treatment was associated with a significant increase in mean lubrication (0.61; 95% CI, 0.25-0.97; P = .001) and decreased pain (0.67; 95% CI, 0.25-1.09; P = .002) compared with placebo. Overall, the proportion of women with LSF was significantly lower after t-E2 treatment compared with placebo (67%; 95% CI, 55%-77% vs 76%; 95% CI, 67%-83%; P = .04). For o-CEE there was no significant reduction in the odds of LSF. Conclusions and Relevance: Treatment with t-E2 modestly improved sexual function in early postmenopausal women, but whether it relieved symptoms of distress is not known. Trial Registration: clinicaltrials.gov Identifier: NCT00154180.
RCT Entities:
Importance: Sexual dysfunction, an important determinant of women's health and quality of life, is commonly associated with declining estrogen levels around the menopausal transition. Objective: To determine the effects of oral or transdermal estrogen therapy vs placebo on sexual function in postmenopausal women. Design, Setting, and Participants: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), a 4-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women. Of 727 KEEPS enrollees, 670 agreed to participate in this multicenter ancillary study. Women were 42 to 58 years old, within 36 months from last menstrual period. Data were collected from July 2005 through June 2008 and analyzed from July 2010 through June 2017. Interventions: Women were randomized to either 0.45 mg/d oral conjugated equine estrogens (o-CEE), 50 µg/d transdermal 17β-estradiol (t-E2), or placebo. Participants also received 200 mg oral micronized progesterone (if randomized to o-CEE or t-E2) or placebo (if randomized to placebo estrogens) for 12 days each month. Main Outcomes and Measures: Aspects of sexual function and experience (desire, arousal, lubrication, orgasm, satisfaction, and pain) were assessed using the Female Sexual Function Inventory (FSFI; range, 0-36 points; higher scores indicate better sexual function). Low sexual function (LSF) was defined as an FSFI overall score of less than 26.55. Distress related to low FSFI score (required for the diagnosis of sexual dysfunction) was not evaluated. Results: The 670 participants had a mean (SD) age of 52.7 (2.6) years. The t-E2 treatment was associated with a significant yet moderate improvement in the FSFI overall score across all time points compared with placebo (average efficacy, 2.6; 95% CI, 1.11-4.10; adjusted P = .002). With o-CEE treatment, there was no significant difference in FSFI overall score compared with placebo (mean efficacy, 1.4; 95% CI, -0.1 to 2.8; adjusted P = .13). There was no difference in FSFI overall score between the t-E2 and o-CEE groups on average across 48 months (adjusted P = .22). In the individual domains of sexual function, t-E2 treatment was associated with a significant increase in mean lubrication (0.61; 95% CI, 0.25-0.97; P = .001) and decreased pain (0.67; 95% CI, 0.25-1.09; P = .002) compared with placebo. Overall, the proportion of women with LSF was significantly lower after t-E2 treatment compared with placebo (67%; 95% CI, 55%-77% vs 76%; 95% CI, 67%-83%; P = .04). For o-CEE there was no significant reduction in the odds of LSF. Conclusions and Relevance: Treatment with t-E2 modestly improved sexual function in early postmenopausal women, but whether it relieved symptoms of distress is not known. Trial Registration: clinicaltrials.gov Identifier: NCT00154180.
Authors: S Mitchell Harman; Dennis M Black; Frederick Naftolin; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; Paul N Hopkins; Rogerio A Lobo; JoAnn E Manson; George R Merriam; Virginia M Miller; Genevieve Neal-Perry; Nanette Santoro; Hugh S Taylor; Eric Vittinghoff; Mingzhu Yan; Howard N Hodis Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: R J Chetkowski; D R Meldrum; K A Steingold; D Randle; J K Lu; P Eggena; J M Hershman; N K Alkjaersig; A P Fletcher; H L Judd Journal: N Engl J Med Date: 1986-06-19 Impact factor: 91.245
Authors: Ilana B Addis; Stephen K Van Den Eeden; Christina L Wassel-Fyr; Eric Vittinghoff; Jeanette S Brown; David H Thom Journal: Obstet Gynecol Date: 2006-04 Impact factor: 7.661
Authors: Rosemary Basson; Julia I O'Loughlin; Joanne Weinberg; Allan H Young; Tamara Bodnar; Lori A Brotto Journal: Psychoneuroendocrinology Date: 2019-03-08 Impact factor: 4.905
Authors: Kerry Murphy; Marla J Keller; Kathryn Anastos; Shada Sinclair; J Cooper Devlin; Qiuhu Shi; Donald R Hoover; Brian Starkman; Jamie McGillick; Caroline Mullis; Howard Minkoff; Maria Gloria Dominguez-Bello; Betsy C Herold Journal: PLoS One Date: 2019-04-26 Impact factor: 3.752
Authors: Virginia M Miller; Fredrick Naftolin; Sanjay Asthana; Dennis M Black; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; N Maritza Dowling; Carey E Gleason; Howard N Hodis; Muthuvel Jayachandran; Kejal Kantarci; Rogerio A Lobo; JoAnn E Manson; Lubna Pal; Nanette F Santoro; Hugh S Taylor; S Mitchell Harman Journal: Menopause Date: 2019-09 Impact factor: 2.953
Authors: Sharon J Parish; James A Simon; Susan R Davis; Annamaria Giraldi; Irwin Goldstein; Sue W Goldstein; Noel N Kim; Sheryl A Kingsberg; Abraham Morgentaler; Rossella E Nappi; Kwangsung Park; Cynthia A Stuenkel; Abdulmaged M Traish; Linda Vignozzi Journal: J Womens Health (Larchmt) Date: 2021-04-01 Impact factor: 2.681
Authors: V M Miller; H S Taylor; F Naftolin; J E Manson; C E Gleason; E A Brinton; J M Kling; M I Cedars; N M Dowling; K Kantarci; S M Harman Journal: Climacteric Date: 2020-09-03 Impact factor: 3.005
Authors: Laura Faubion; Thomas A White; Brett J Peterson; Jennifer R Geske; Nathan K LeBrasseur; Marissa J Schafer; Michelle M Mielke; Virginia M Miller Journal: Physiol Rep Date: 2020-08